KBI-BIOPHARMA-SA
14.6.2022 13:47:07 CEST | Business Wire | Press release
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, announced today that an expanded, fully-integrated mammalian contract development and manufacturing services facility is now open and operational in Geneva, Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005062/en/
The ~94,000 square-foot integrated KBI/Selexis state-of-the-art facility builds upon the companies’ existing market foothold by combining best-in-class cell line development (CLD) and expert mammalian cell manufacturing in a single location. KBI and Selexis leverage their expertise and efficient end-to-end services for biomanufacturing clients.
This expansion enables industry-leading delivery of client programs through increased quality, efficiency, and time savings across a diverse portfolio of molecule formats. Under one roof, KBI and Selexis provide cell line transfection through cGMP drug manufacturing with Selexis’ specialized high-titer mammalian cell line development technologies and services and KBI’s cGMP bulk drug manufacturing for clinical and commercial requirements.
“This expansion in Geneva will provide our global clients with streamlined capabilities to support mammalian-based therapies,” said Mark W. Womack, Chief Executive Officer for KBI Biopharma and Selexis SA. “With a single touchpoint for best-in-class cell line development, process development, and manufacturing, clients experience heightened access to our process and product-based expertise.”
He added, “This facility expansion, together with our track record in the space, strengthens our commitment to deliver a seamless experience to the European biopharmaceutical community and clients around the globe.”
The fully integrated Selexis and KBI development platform has supported more than 60 clinical development programs with high productivity and robust product quality. The two companies have developed a seamless approach, to optimize the client experience.
“We have always been a science-driven, customer-centric company. This expansion in Geneva helps our clients optimize their complex biomanufacturing processes under accelerated timelines,” said Ulrich Valley, Senior Vice President, Operations & Site Head, KBI Biopharma, Geneva.
The KBI Biopharma facility will create more than 200 technical positions in development, operations, and quality assurance. The facility includes a suite of analytical testing laboratories and dual 2,000L single-use cGMP manufacturing trains with downstream processes capable of producing 8-10 kg yields per batch.
With the expanded Geneva facility now operational, KBI and Selexis will celebrate with ribbon-cutting activities and facility tours starting in July 2022.
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com .
About Selexis SA.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. Our global partners have utilized Selexis technologies to advance more than 158 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Epicor Prism Launches Across European Markets, Bringing Embedded, Industry-Specific AI to Manufacturers23.6.2026 17:55:00 CEST | Press release
New AI capabilities help organisations enhance operational decision-making Epicor has expanded its AI-driven ERP strategy in the UK and select European markets with the general availability of Epicor Prism, a portfolio of vertical AI agents designed specifically for the supply chain industries. Embedded directly in Epicor Kinetic, Epicor Prism gives customers conversational access to live ERP data and related documents without needing specialised analytics skills or separate AI tools. The launch reflects a broader shift in ERP from systems of record to systems of outcomes that help users interpret data, make decisions and take action in real time — a transformation Epicor calls Cognitive ERP. Responding to pressure on productivity and skills European manufacturers are under growing pressure to raise productivity, strengthen supply chain resilience and remain globally competitive despite workforce constraints and ongoing digital skills shortages. While many organisations continue to inv
Airship Appoints Laura Zwahlen as Chief Revenue Officer23.6.2026 17:00:00 CEST | Press release
Go-To-Market and Revenue Operations Veteran to Lead Global Sales and Customer Success Organizations into the Next Phase of Growth Airship, the mobile-first customer experience company, today announced the appointment of Laura Zwahlen as Chief Revenue Officer (CRO). Zwahlen will oversee all global revenue-generating activities, driving the alignment, execution, and strategy across Airship’s sales, account management, and customer success teams to accelerate the company’s market leadership and customer impact. She will report directly to CEO Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623145620/en/ Laura Zwahlen, Chief Revenue Officer (CRO) of Airship Zwahlen brings more than 20 years of go-to-market and revenue leadership experience, with a proven track record of guiding technology organizations through rapid growth, strategic acquisitions, and public offerings. Previously, she served as CRO at NextRoll (th
INRIX Data Reveals How the 2026 FIFA World Cup Is Reshaping Traffic Across 11 U.S. Cities23.6.2026 16:56:00 CEST | Press release
With unsurpassed data scale and speed, INRIX is the definitive ongoing source for World Cup transportation analysis INRIX, a global leader in transportation data and analytics, today announced the launch of its 2026 FIFA World Cup Data Hub, providing transportation agencies, event organizers, media, and travelers with a comprehensive, real-time view of how the world’s largest sporting event is moving millions of people. The 2026 FIFA World Cup spans 16 cities across the United States, Canada, and Mexico, making it the most geographically diverse World Cup in history. With matches across 11 U.S. stadiums attracting millions of fans from around the world, transportation demands vary as widely as the cities themselves. INRIX is uniquely positioned to capture that complexity at scale with unprecedented speed, backed by a data infrastructure no other company can beat. Drawing on more than 300 million connected vehicles and devices, a 50-petabyte transportation data lake, and 44 billion data
IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term23.6.2026 16:41:00 CEST | Press release
New research introduces a family of error-correcting codes that reduce qubit overhead by up to 1,000 times compared to today’s leading approach — without requiring any new hardware. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced a significant achievement in quantum error correction, using directional tile codes, marking a major step toward practical, large-scale fault-tolerant quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623243333/en/ IQM achieves milestone in quantum error correction, enabling fault-tolerant computing in the near-term The research, available on arXiv, and co-authored by IQM researchers and collaborators at Freie Universität Berlin, the University of Edinburgh, and Johannes Gutenberg-Universität Mainz, introduces ‘directional tile codes’, a new family of quantum error-correcting codes that resolves one of the central tensions in quantum
NetApp Enhances Support for AI Workloads at Massive Scale23.6.2026 16:00:00 CEST | Press release
StorageGRID 12.1 delivers up to 12TB/s throughput and massive scale for AI workloads NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced the release of StorageGRID 12.1, designed to help customers scale AI and other modern workloads with a federated global namespace. The new capabilities improve how data is accessed, processed, and managed across distributed environments to support AI data pipelines, data lakes, and modern object-based applications. Organizations are contending with rapid growth in unstructured data to serve AI workloads while also managing that data across increasingly distributed hybrid environments. In its Object Storage Solutions Landscape, Q1 2026 report, Forrester notes that the rise of generative AI has pushed object storage further into an AI‑optimized data platform beyond its historical uses supporting enterprise data strategies with scalable, durable storage for unstructured data, media, and backups. The updates to NetApp Stor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom